These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 17344466)

  • 1. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
    DeAngelo DJ; Yu D; Johnson JL; Coutre SE; Stone RM; Stopeck AT; Gockerman JP; Mitchell BS; Appelbaum FR; Larson RA
    Blood; 2007 Jun; 109(12):5136-42. PubMed ID: 17344466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
    Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R
    Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
    Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
    Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
    Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
    Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
    Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
    Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
    Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
    Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
    Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
    Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
    Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.